
Loading, please wait...

Loading, please wait...

Spinal cord stimulator placement remains a gold-standard treatment for patients suffering from refractory chronic back and leg pain. Historically, clinicians preferred hospital settings for thoracic paddle lead implantation due to potential perioperative risks. However, recent data suggests that ambulatory surgery centers (ASCs) may offer a safe and efficient alternative. This transition could significantly reduce healthcare costs while maintaining high standards of patient care.
Researchers recently conducted a retrospective cohort study involving 369 adult patients. The study compared 222 patients who underwent surgery in an ASC with 147 patients treated in a hospital setting. Initially, the hospital group presented with higher body mass index (BMI) levels, more comorbidities, and lower education levels. Consequently, these baseline differences required a propensity score-matching analysis to ensure a fair comparison of outcomes.
The study results revealed several benefits for the ASC group. Specifically, patients treated in the ASC experienced shorter mean operative durations and significantly shorter lengths of stay. Furthermore, the analysis showed no significant differences between the two groups regarding returns to the operating room or 3-month postoperative patient satisfaction. Although hospital patients initially had higher readmission rates, this difference disappeared after matching for confounding variables.
Patient-reported outcome measures (PROMs) were consistent across both environments. Both groups reported similar improvements in back pain, leg pain, and overall quality of life. This evidence suggests that, for appropriately selected patients, the ASC setting does not compromise clinical efficacy or patient safety. Therefore, surgeons may confidently consider ASCs for thoracic paddle lead placement in stable patients without complex comorbidities.
Yes, for appropriately selected patients, research shows that safety outcomes, including complication rates and returns to the operating room, are comparable between both settings.
Patients in ASC settings often benefit from shorter operative times and faster discharge. Additionally, ASCs can be more cost-effective for both the patient and the healthcare system.
Studies indicate no significant difference in patient satisfaction or 3-month clinical outcomes when comparing ASCs and hospital settings for SCS lead placement.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Zeitouni D et al. Are ambulatory surgery centers a safe and effective setting for spinal cord stimulator placement? Neurosurg Focus. 2026 Apr 01. doi: 10.3171/2026.1.FOCUS251086. PMID: 41921228.
Smith H, et al. Safety of Thoracic Paddle Lead Spinal Cord Stimulator Implantation in an Ambulatory Surgery Center. PubMed. 2023 Feb 15.
Grider JS, et al. Global Trends in Ambulatory Spine Surgery and Neuromodulation. Pain Physician Journal. 2024; 27:69-77.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study comparing SCS thoracic paddle lead placement in ASCs vs. hospitals found that ASC settings offer comparable safety and efficacy for selected patient...
6 months ago

A recent study demonstrates that spinal oxygen sensors do not require mitochondrial electron transport to trigger sympathetic excitation during acute hypoxia, revealing new insights into how mitochondrial oxidative stress modulates autonomic tone in cardiovascular and neurological diseases.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A novel calcium polyphosphate coacervate enables injectable bone implants with in situ hierarchical porosity via phase separation and gas foaming, significantly enhancing cell proliferation, energy metabolism, and osteogenic differentiation for minimally invasive bone defect repair.
Today

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today